Belantamab mafodotin (anti-BCMA) 是由人源化、聚焦化的抗 B 细胞成熟抗原 (BCMA) 单克隆抗体和 McMMAF 组成,具有抗骨髓瘤活性。
Belantamab mafodotin (anti-BCMA) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity.
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK.
宿主种属
人(Human)
特异性
TNFRSF17
种属反应性
人(Human),食蟹猴(Cynomolgus monkey)
偶联
MC-VC-PAB-MMAF
作用类型
结合剂
作用机制
B 细胞成熟抗原抗体
克隆类型
重组抗体
Format
Whole IgG
亚型
Human IgG1
轻链亚型
kappa
纯化方法
Protein A purified
纯度
>90% (SDS-PAGE&SEC)
浓度
见COA
CAS编号和信息
2050232-20-5
分子类型
抗体偶联药物
产品线
生物产品
储存与运输
物理外观
Liquid
储存缓冲液
Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂
No
储存条件
-80℃储存,避免反复冻融
运输条件
特低温运输
稳定性与储存
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
图片
Belantamab mafodotin (anti-BCMA) (Ab175467) - Flow Cytometry Flow Cytometry analysis of U266 cells labelling BCMA (red) with Belantamab mafodotin (anti-BCMA) (Ab175467) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Belantamab mafodotin (anti-BCMA) (Ab175467) - ELISA Immobilized Recombinant Human BCMA/TNFRSF17(Fc) protein (rp169554) at 1.0 μg/mL can bind Belantamab mafodotin (anti-BCMA) (Ab175467) with the EC50 of 40.09 ng/mL.
Belantamab mafodotin (anti-BCMA) (Ab175467) - ELISA Immobilized Recombinant huBCMA- ECD-His protein at 2.0 μg/mL can bind Belantamab mafodotin (anti-BCMA) (Ab175467) with the EC50 of 26.34 ng/mL.
Belantamab mafodotin (anti-BCMA) (Ab175467) - SEC The purity of Belantamab mafodotin (anti-BCMA) (Ab175467) is more than 95% verified by HPLC.